BNP Paribas Financial Markets Sells 46,233 Shares of Insulet Corporation $PODD

BNP Paribas Financial Markets lowered its position in shares of Insulet Corporation (NASDAQ:PODD) by 38.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,466 shares of the medical instruments supplier’s stock after selling 46,233 shares during the period. BNP Paribas Financial Markets owned 0.11% of Insulet worth $21,166,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Larson Financial Group LLC increased its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period. Elyxium Wealth LLC bought a new position in Insulet during the 4th quarter worth $28,000. Fideuram Asset Management Ireland dac bought a new position in Insulet during the 4th quarter worth $41,000. Measured Wealth Private Client Group LLC bought a new position in Insulet during the 3rd quarter worth $49,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth $51,000.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 0.36% of the stock is owned by insiders.

Insulet Price Performance

PODD stock opened at $153.22 on Friday. Insulet Corporation has a 52-week low of $140.63 and a 52-week high of $354.88. The business has a 50-day simple moving average of $175.73 and a two-hundred day simple moving average of $238.90. The company has a market capitalization of $10.61 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the business earned $1.02 EPS. The company’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts expect that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. Sanford C. Bernstein decreased their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Citigroup decreased their price target on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. Leerink Partners decreased their price target on Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Canaccord Genuity Group decreased their price target on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, Barclays dropped their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.